CLINICAL_TRIALS
trial_result
· 2017-12-08
Clinical Trial Update: Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma [Phase 2]
Summary
Phase 2 trial investigating bortezomib and bendamustine for relapsed/refractory multiple myeloma; study terminated with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NYU Langone Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-12-08